J Skarda, E Fridman, P Plevova, M Hajduch, E Ofek, J Kopolovic, Z Kolar
hmlh1, hmsh2, mismatch repair, non-small cell lung cancer, prognosis
J Skarda, E Fridman, P Plevova, M Hajduch, E Ofek, J Kopolovic, Z Kolar. Prognostic Value Of hMLH1 and hMSH2 Immunohistochemical Expression In Non-Small Cell Lung Cancer. The Internet Journal of Pulmonary Medicine. 2005 Volume 6 Number 1.
Lung cancer has become the leading cause of cancer death in many industrialized countries. In Taiwan, for example, lung cancer claims more than 7,000 lives annually . Much attention has recently been focused on the rapidly increasing incidence of primary lung cancer in nonsmokers [14, 21, 28]. Gender differences in distribution, histological type, and exposure to tobacco have also been noted [4,6,8,16,18]. Although 80% of female lung cancer patients worldwide have smoked at some time, less than 10% of Taiwanese women with lung cancer have any smoking history. The low smoking status and high incidence rate of adenocarcinoma constitute distinctive characteristics of lung cancer in Taiwanese females. Ryberg et al. showed that susceptibility to DNA damage caused by environmental carcinogens such as polycyclic aromatic hydrocarbon–like compounds may be higher among women than among men. They concluded that women are at greater risk of tobacco and/or environmentally-induced lung cancer [19,]. Takagi et al. observed a distinct mutational spectrum for the
Molecular biological studies have shown that overt cancers carry multiple genetic and epigenetic alterations, which seem to indicate the involvement of tumor suppressor genes and dominant oncogene activation during the process of carcinogenesis and subsequent progression of cancer [20,25,]. Alteration analysis of genes controlling acquired somatic mutations, such as genes involved in DNA repair, may explain the observed susceptibility to various environmental factors seen in lung cancer in nonsmoking females.
The clinical significance of protein expression of
In the present study we investigated protein expression in
Materials and Methods
Study population and tumor samples
105 patients diagnosed with NSCLC and operated on between 1996 and 2001 were enrolled in this study. There was complete follow-up for all patients. The end of the follow-up period was defined as October 2005. Overall survival was calculated from the day of surgery to the date of death or the last follow-up. Cancer-specific survival was calculated from the day of surgery to the date of either lung cancer death or the last follow-up. The mean follow-up period for all patients was 32 months (range: 0.5-78 months). Of 105 patients 40% (42) patients died from lung cancer and had a median cancer-specific survival of 17 months (range: 0.5-44 months).
Analysis of protein expression: immunohistochemistry assay
Paraffin blocks of tumors were cut into 5-µm slices and then processed using protocols described previously [26,]. hMLH1 and hMSH2 protein expression was evaluated by immunohistochemistry. The monoclonal antibodies used for the hMLH1 protein were G168-728 (1:250; PharMingen, San Diego, CA) and for the hMSH2 protein FE11 (1:50; Oncogene Science, Cambridge, MA). The normal staining pattern for hMLH1 and hMSH2 is nuclear. Absence of nuclear staining in tumor cells along with positive staining in infiltrating lymphocytes was considered negative.
The Pearson χ 2 test was used to compare the hMLH1 and hMSH2 alterations among cases and between various clinicopathologic variables. The difference in age distribution between patients with and without the alteration was analyzed by the independent sample
In this study, we investigated the significance of the DNA mismatch repair genes,
Data on mismatch repair gene alterations in lung cancer is scarce. Xinarianos et al. studied 59 males and 91 females with lung cancer in the United Kingdom and showed reduced expression levels of hMLH1 and hMSH2 proteins in 53% and 82% of adenocarcinoma specimens respectively [29,]. These results are similar to ours except for the higher expression level of hMSH2 protein in their study. On the other hand, an immunohistochemical study by Aubry et al. showed that mismatch repair proteins hMLH1, hMSH2, and hMSH6 were not inactivated in 33 bronchioloalveolar carcinomas of the lung [1,]. This type of inconsistency also occurred in a U.S. study, which found no promoter methylation of the hMLH1 gene in 20 NSCLC tumors in a methylation-specific PCR (MSP) assay [9,]. In a panel of 21 small cell lung cancer cell lines using the MSP assay Hansen et al. showed that low hMLH1 protein expression was not linked to promoter methylation [11,]. The discrepancies between the various studies may be due to differences in clinicopathological variables. In addition, the methylation regions examined and sensitivities of the assays used in the various studies were different. It is also possible that geographic and/or ethnic factors may account for frequent
Some authors have suggested that a relationship exists between the expression of hMLH1 and hMSH2 proteins and cancer drug resistance or response [2,13,17,]. Strathdee et al. investigated the role of methylation of
The association between DNA inactivation of mismatch repair genes and genetic instablility has been described in some cancers. Loss of
Interestingly, Ward et al. [27,] have reported that the poor prognostic effect of DNA methylation is lost in colorectal patients with microsatellite instability. It seems that methylated tumors, both unstable and stable, have distinct clinicopathologic features. Further analysis regarding lung cancer is necessary. Mechanisms involving DNA damage signaling, promoter hypermethylation of mismatch repair genes, and target drug-resistant genes after chemotherapy should also be further investigated.
This work has been dedicated to grant number IGA MZ čR NR/8425-3/2005 of the Ministry of Health in Czech Republic.
Josef Skarda, MD Department of Pathology, Medical Faculty, Palacky University, Hnevotinska 3, CZ-77515, Olomouc, Czech Republic email@example.com Tel/Fax.: 004-2060-3436129
Eduard Fridman, MD Department of Pathology, Chaim Sheba Medical Center, Sackler School of Medicine Tel-Aviv University, Tel-Hashomer 52621 Israel firstname.lastname@example.org Tel.: 972-3-5302354 Fax: 972-3-5302381